<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621385</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VLY-686-1102</org_study_id>
    <nct_id>NCT02621385</nct_id>
  </id_info>
  <brief_title>Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects</brief_title>
  <official_title>An Open-label, Single-sequence Study to Assess the Effect of Multiple Doses of Tradipitant on Cytochrome P450 3A4 Using Midazolam as a Substrate in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the potential effect of administration of tradipitant on&#xD;
      CYP3A4 using midazolam pharmacokinetics as markers.&#xD;
&#xD;
      The study will also further characterize the pharmacokinetics of tradipitant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Midazolam Area Under the Curve (AUC)</measure>
    <time_frame>Pre-dose,0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Midazolam time to maximal plasma concentration (Tmax)</measure>
    <time_frame>Pre-dose,0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Midazolam maximal plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose,0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, and 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>α-hydroxymidazolam area under the curve(AUC)</measure>
    <time_frame>pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>α-hydroxymidazolam time to maximal plasma concentration (Tmax)</measure>
    <time_frame>pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>α-hydroxymidazolam maximal plasma concentration (Cmax)</measure>
    <time_frame>pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tradipitant and tradipitant metabolites area under the curve (AUC)</measure>
    <time_frame>pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tradipitant and tradipitant metabolites time to maximal plasma concentration (Tmax)</measure>
    <time_frame>pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tradipitant and tradipitant metabolites maximal plasma concentration (Cmax)</measure>
    <time_frame>pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of multiple oral doses of tradipitant alone and in combination with midazolam by spontaneous reporting of AEs measured by events related to treatment.</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of multiple oral doses of tradipitant alone and in combination with midazolam by number of participants with abnormal laboratory values</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of multiple oral doses of tradipitant alone and in combination with midazolam by number of participants with abnormal ECG values</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of multiple oral doses of tradipitant alone and in combination with midazolam by number of participants with abnormal vital signs</measure>
    <time_frame>19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The Columbia Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation</measure>
    <time_frame>Baseline, Day 10, Day 19</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Tradipitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tradipitant</intervention_name>
    <description>test agent</description>
    <arm_group_label>Tradipitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>substrate for drug-drug interaction assessment</description>
    <arm_group_label>Tradipitant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability and acceptance to provide written informed consent;&#xD;
&#xD;
          2. Subjects must be males or females between 18 and 55 years of age, inclusive;&#xD;
&#xD;
          3. Female subjects of childbearing potential must be non-pregnant and non-lactating and&#xD;
             have a negative serum or urine pregnancy test at the Screening visit and at Check-in&#xD;
             (Days -1) and agree not to attempt to become pregnant during the course of the study.&#xD;
             Female subjects of childbearing potential (including peri-menopausal women who have&#xD;
             had a menstrual bleeding within 1 year) must be using appropriate birth control (e.g.&#xD;
             intrauterine device [IUD], diaphragm or condom with spermicidal jelly or foam or&#xD;
             cervical cap) for a period of 35 days before the first dosing, for the duration of the&#xD;
             study, and recommended to use it for one month after the last dose. Women are&#xD;
             considered to be not of childbearing potential if they have been surgically sterilized&#xD;
             (physician-documented hysterectomy or tubal ligation);&#xD;
&#xD;
             a. Note: Women are not permitted to use hormonal methods of birth control (e.g. oral&#xD;
             contraceptives, hormonal intrauterine device [IUD], patch and steroids) and must use&#xD;
             another acceptable method of birth control during the study and recommended to use it&#xD;
             for one month after the last dose. Women currently taking oral contraceptives will be&#xD;
             required to discontinue their regimen at least two weeks prior to first dosing.&#xD;
&#xD;
          4. Subjects with Body Mass Index (BMI) of ≥18 and ≤33kg/m2 (BMI = weight (kg)/ [height&#xD;
             (m)]2);&#xD;
&#xD;
          5. Vital signs (after 3 minutes resting in sitting position) which are within the ranges&#xD;
             shown below:&#xD;
&#xD;
               1. Body temperature between 35.0-37.5 °C;&#xD;
&#xD;
               2. Systolic blood pressure between 90-150 mmHg;&#xD;
&#xD;
               3. Diastolic blood pressure between 50-95 mmHg;&#xD;
&#xD;
               4. Pulse rate between 50-100 beats per minute&#xD;
&#xD;
          6. Willing and able to comply with study requirements;&#xD;
&#xD;
          7. Subjects must be in good health as determined by past medical history, physical&#xD;
             examination, electrocardiogram, clinical laboratory tests and urinalysis;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of recent (within six months) drug or alcohol abuse as defined in DSM IV,&#xD;
             Diagnostic Criteria for Drug and Alcohol Abuse or evidence of such abuse as indicated&#xD;
             by the laboratory assays conducted during the Screening visit or at Check-in;&#xD;
&#xD;
          2. Any major surgery within three months of Day 1 or any minor surgery within one month;&#xD;
&#xD;
          3. Donation or loss of 400 mL or more of blood within 3 months prior to the Baseline&#xD;
             Visit;&#xD;
&#xD;
          4. History or current evidence of cardiovascular, hepatic, hematopoietic, renal,&#xD;
             gastrointestinal or metabolic dysfunction judged by the Investigator to be clinically&#xD;
             significant;&#xD;
&#xD;
          5. Any condition requiring the regular use of medication;&#xD;
&#xD;
          6. History of intolerance and/or hypersensitivity to drugs including midazolam,&#xD;
             tradipitant, or a medications similar to tradipitant and its accompanying excipients&#xD;
             within the past two months prior to Day 1;&#xD;
&#xD;
          7. History (including family history) or current evidence of congenital long QT syndrome&#xD;
             or known acquired QT interval prolongation;&#xD;
&#xD;
          8. Subjects who are currently considered at suicide risk, any subject who has ever made a&#xD;
             suicide attempt, or those who are currently demonstrating active (within the past 6&#xD;
             months) suicidal ideation as deemed by the Columbia Suicide Severity Rating Scale (C-&#xD;
             SSRS);&#xD;
&#xD;
          9. History of liver disease and/or positive for one or more of the following serological&#xD;
             results:&#xD;
&#xD;
               1. a positive hepatitis C antibody test (anti-HCV)&#xD;
&#xD;
               2. a positive HIV (ELISA and Western-to confirm positive finding) test result c.&#xD;
                  positive hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
         10. Treatment with any drug known to cause major organ system toxicity (e.g.,&#xD;
             chloramphenicol or tamoxifen) during the 60 days preceding Day 1;&#xD;
&#xD;
         11. Elevated (&gt; 2 times the upper limit of normal) liver function tests (i.e.&#xD;
&#xD;
             aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), and&#xD;
             total bilirubin);&#xD;
&#xD;
         12. Inability to be venipunctured and/or tolerate venous access;&#xD;
&#xD;
         13. Subjects who have used tobacco products 3 months prior to dosing. Tobacco users will&#xD;
             be defined as any subject who reports cigarette, cigar, tobacco, nicotine gum,&#xD;
             nicotine patch or electronic cigarette use;&#xD;
&#xD;
         14. Consumption of &gt;1 drink/day of alcohol for females and &gt;2 drinks/day for males,&#xD;
             defined according to the USDA Dietary Guidelines 2010 ;&#xD;
&#xD;
         15. Consumption of &gt;5 cups coffee/tea/day;&#xD;
&#xD;
         16. Participation in the evaluation of any investigational product for 3 months before&#xD;
             this study. The 3-month interval is calculated as the time between the first calendar&#xD;
             day of the month that follows the last visit of the previous study and the first day&#xD;
             of the present study;&#xD;
&#xD;
         17. Use of prescription or OTC medications, including herbal products (e.g., St. John's&#xD;
             Wort) within 2 weeks of Day 1;&#xD;
&#xD;
         18. Use of any food or beverage containing alcohol, grapefruit or grapefruit juice, apple&#xD;
             or orange juice, vegetables from the mustard green family (e.g. kale, broccoli,&#xD;
             watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meat&#xD;
             within 1 week before Day 1;&#xD;
&#xD;
         19. Abnormal diets (&lt;1600 or &gt;3500 kcal/day), substantial changes in eating habits in the&#xD;
             4 weeks before this study, or vegetarians;&#xD;
&#xD;
         20. Participation in a previous LY686017 or VLY-686/tradipitant trial;&#xD;
&#xD;
         21. Anyone affiliated with the site or sponsor and/or anyone who may consent under duress;&#xD;
&#xD;
         22. Any other sound medical reason as determined by the clinical Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko Radicioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CROSS Research SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Arzo</city>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

